On July 23rd, guided by the Drug Evaluation Center of the State Food and Drug Administration, Shanghai Municipal Commission of Economy and Informatization and the Administrative Committee of Lingang New Area of China (Shanghai) Pilot Free Trade Zone, the first "China Lingang Biomedical Innovation and Development Summit" 2021 Gene Therapy Product R&D Theme Forum sponsored by the Pharmaceutical Toxicology Committee of Chinese Pharmacological Society and Shanghai Pharmacological Society was successfully held at Life Blue Bay of Lingang New Area. Liu Ping, Vice Chairman of Shanghai Municipal Commission of Economy and Informatization, and Wu Xiaohua, Deputy Secretary of CPC Working Committee of Lingang New Area, attended the meeting.
The theme of the first "China Lingang Biomedical Innovation and Development Summit" is "Focusing on the Frontier of Gene Therapy and Boosting the Development of Emerging Industries". This forum included three special seminars. More than 10 leading experts from drug evaluation, regulatory authorities and gene therapy were invited, who had face-to-face exchange of many topics in the R&D of gene therapy products and made detailed academic presentations on the interpretation of policy guidelines of regulatory agencies, R&D progress at home and abroad, and key points and strategies from CMC to non-clinical and clinical stages. During the panel discussion, it also conducted in-depth discussions on the current hot issues and pain points in this field, so as to contribute ideological wisdom and directional guidance to the development of the industry and promote the high-quality evolution of gene therapy product R&D at Lingang New Area, in Shanghai and even across China.
